New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMFYA is t...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Wonder drug set to help millions of NHS patients
Adalimumab, known by the brand name Humira, dampens the inflammation that causes the joint pain and swelling of rheumatoid arthritis. (Source: the Mail online | Health)
Source: the Mail online | Health - April 17, 2021 Category: Consumer Health News Source Type: news
Efficacy and Safety of Adalimumab Biosimilar CT-P17 for RA Efficacy and Safety of Adalimumab Biosimilar CT-P17 for RA
Is this adalimumab biosimilar for the treatment of rheumatoid arthritis as safe and effective as the reference product?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 26, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Adalimumab Earns FDA Approval for Ulcerative Colitis in Children Adalimumab Earns FDA Approval for Ulcerative Colitis in Children
Adalimumab has received approval from the Food and Drug Administration for use in pediatric patients aged 5 years and older with moderately to severely active ulcerative colitis.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 3, 2021 Category: Gastroenterology Tags: Pediatrics News Alert Source Type: news
Humira (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Humira (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 24, 2021 Category: Drugs & Pharmacology Source Type: news
Adalimumab Enhances Primary Wound Closure After HS Surgery Adalimumab Enhances Primary Wound Closure After HS Surgery
' Our experience suggests that under the effects of treatment with adalimumab, wound healing disorders with primary wound closure occur less often, ' Gefion Girbig, MD, reported at the EADV Congress.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 3, 2021 Category: Dermatology Tags: Dermatology News Source Type: news
Drugmaker AbbVie reports 'strong' fourth-quarter and fiscal 2020 results
Strong sales of arthritis drug Humira and new Botox products helped in the quarter and fiscal year. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 3, 2021 Category: Health Management Authors: Ben Miller Source Type: news
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... Biopharmaceuticals, Regulatory Innovent Biologics, SULINNO , adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 23, 2020 Category: Pharmaceuticals Source Type: news
Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community, BMJ
The AVID-CC trial, funded through the Covid-19 Therapeutics Accelerator, will investigate whether adalimumab (two doses being evaluated) is effective in the treatment of adults in community care settings. Treatment will be delivered by Hospital at Home teams around the UK. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 5, 2020 Category: Consumer Health News Source Type: news
Oxford to Study Anti-inflammatory Drug Humira as Potential COVID-19 Treatment Oxford to Study Anti-inflammatory Drug Humira as Potential COVID-19 Treatment
Oxford University said on Wednesday it would study whether the world ' s best-selling prescription medicine, adalimumab, was an effective treatment for COVID-19 patients.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 1, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Arthritis drug to be trialled as Covid treatment in UK care homes
Adalimumab could counter hyper-inflammation seen in severe coronavirus casesCoronavirus – latest updatesSee all our coronavirus coverageA commonly used arthritis drug is to be trialled with care home residents who have Covid, after it was observed that those taking it for their joint pains were less likely to end up in hospital with the virus.Older people in care homes, who often have some degree of dementia, tend not to do well in hospital, where they become more confused and may pick up infections. The trial will break new ground by giving the drug to people at care homes, where they can be supervised and monitored aft...
Source: Guardian Unlimited Science - September 29, 2020 Category: Science Authors: Sarah Boseley Health editor Tags: Coronavirus outbreak UK news Medical research Older people Social care Health NHS Drugs Infectious diseases Science Society Source Type: news
Secukinumab Not Superior to Adalimumab in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - September 26, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
SAN FRANCISCO, U.S. and SUZHOU, China, Sept. 3, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medici... Biopharmaceuticals, Regulatory Innovent Biologics, SULINNO , adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 3, 2020 Category: Pharmaceuticals Source Type: news
Hulio (Adalimumab-fkjp njection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 16, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira
HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 9, 2020 Category: Drugs & Pharmacology Source Type: news
